197 related articles for article (PubMed ID: 15635690)
1. Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen.
Schuman JT; Grinstead JS; Apostolopoulos V; Campbell AP
Biopolymers; 2005 Feb; 77(2):107-20. PubMed ID: 15635690
[TBL] [Abstract][Full Text] [Related]
2. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
Grinstead JS; Schuman JT; Campbell AP
Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
[TBL] [Abstract][Full Text] [Related]
3. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
4. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
[TBL] [Abstract][Full Text] [Related]
5. Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat.
Brokx RD; Revers L; Zhang Q; Yang S; Mal TK; Ikura M; Gariépy J
Biochemistry; 2003 Dec; 42(47):13817-25. PubMed ID: 14636048
[TBL] [Abstract][Full Text] [Related]
6. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antibody recognition of synthetic antigens from MUC1.
Bánóczi Z; Mezõ G; Windberg E; Uray K; Majer Z; Hudecz F
J Pept Sci; 2008 May; 14(5):610-6. PubMed ID: 17975847
[TBL] [Abstract][Full Text] [Related]
9. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation.
Karsten U; Diotel C; Klich G; Paulsen H; Goletz S; Müller S; Hanisch FG
Cancer Res; 1998 Jun; 58(12):2541-9. PubMed ID: 9635576
[TBL] [Abstract][Full Text] [Related]
10. MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats.
Kam JL; Regimbald LH; Hilgers JH; Hoffman P; Krantz MJ; Longenecker BM; Hugh JC
Cancer Res; 1998 Dec; 58(23):5577-81. PubMed ID: 9850097
[TBL] [Abstract][Full Text] [Related]
11. Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1).
Karsten U; Serttas N; Paulsen H; Danielczyk A; Goletz S
Glycobiology; 2004 Aug; 14(8):681-92. PubMed ID: 15115750
[TBL] [Abstract][Full Text] [Related]
12. Binding of tumor antigen mucin (MUC1) derived peptides to the heat shock protein DnaK.
Schreiber J; Stahn R; Schenk JA; Karsten U; Pecher G
Anticancer Res; 2000; 20(5A):3093-8. PubMed ID: 11062727
[TBL] [Abstract][Full Text] [Related]
13. Design of a MUC1-based cancer vaccine.
Hanisch FG
Biochem Soc Trans; 2005 Aug; 33(Pt 4):705-8. PubMed ID: 16042579
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Pepscan analyses for epitope mapping of anti-MUC1 monoclonal antibodies--a comparative study and review of five antibodies.
Petrakou E; Murray A; Rosamund C; Graves L; Price MR
Anticancer Res; 1998; 18(6A):4419-21. PubMed ID: 9891503
[TBL] [Abstract][Full Text] [Related]
15. Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses.
von Mensdorff-Pouilly S; Kinarsky L; Engelmann K; Baldus SE; Verheijen RH; Hollingsworth MA; Pisarev V; Sherman S; Hanisch FG
Glycobiology; 2005 Aug; 15(8):735-46. PubMed ID: 15814824
[TBL] [Abstract][Full Text] [Related]
16. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
17. Malignancy-induced autoimmunity to MUC1: initial antibody characterization.
Graves CR; Robertson JF; Murray A; Price MR; Chapman CJ
J Pept Res; 2005 Dec; 66(6):357-63. PubMed ID: 16316451
[TBL] [Abstract][Full Text] [Related]
18. Epitope mapping of anti-MUC1 mucin protein core monoclonal antibodies.
Petrakou E; Murray A; Price MR
Tumour Biol; 1998; 19 Suppl 1():21-9. PubMed ID: 9422085
[TBL] [Abstract][Full Text] [Related]
19. Functional neoglycopeptides: synthesis and characterization of a new class of MUC1 glycoprotein models having core 2-based O-glycan and complex-type N-glycan chains.
Matsushita T; Sadamoto R; Ohyabu N; Nakata H; Fumoto M; Fujitani N; Takegawa Y; Sakamoto T; Kurogochi M; Hinou H; Shimizu H; Ito T; Naruchi K; Togame H; Takemoto H; Kondo H; Nishimura S
Biochemistry; 2009 Nov; 48(46):11117-33. PubMed ID: 19852465
[TBL] [Abstract][Full Text] [Related]
20. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
